Business context and reporting period
Belite Bio, Inc. filed this Form 20-F for the fiscal year ended December 31, 2022. It is an annual report, not a standalone fourth-quarter filing; quarterly financial results are not separately provided in the supplied filing text. The Cayman Islands-incorporated company is a clinical-stage biopharmaceutical developer with no approved products and no product-sale revenue. Its lead candidate, oral once-daily tinlarebant (LBS-008), is being developed for Stargardt disease type 1 (STGD1) and geographic atrophy (GA); LBS-009 is in preclinical development for metabolic diseases.
Financial and operating highlights
| Metric | FY2022 | FY2021 | Change or context |
|---|---|---|---|
| Revenue | None | None | No product revenue generated |
| Research and development expense | $8.9 million | $7.4 million | Up 19.5% |
| General and administrative expense | $4.0 million | $2.4 million | Up 66.2% |
| Total operating expense / operating loss | $12.8 million | $9.8 million | Operating loss increased 30.9% |
| Net loss | $12.6 million | $9.7 million | Increased 30.9%; FY2020 net loss was $5.8 million |
| Net loss per ordinary share, basic and diluted | $0.63 | $1.01 | Loss per share decreased, with weighted-average shares rising to 20.0 million from 9.6 million |
| Net cash used in operating activities | $11.5 million | $7.5 million | Cash use increased; FY2020 was $4.4 million |
| Cash at year-end | $42.1 million | $17.3 million | Increase primarily funded by the 2022 IPO |
Other income was $173,000, including $166,000 of other income primarily attributed to foreign-exchange gains; interest expense was $16,000. Foreign-currency translation produced a $196,000 loss in other comprehensive income. Profit margins are not meaningful because the company had no revenue. The filing reports no income-tax expense for 2021 or 2022.
At December 31, 2022, total assets were $44.3 million, including $42.1 million cash; current liabilities were $2.1 million and total liabilities were $2.8 million. The company reported $866,000 of operating lease liabilities, including $198,000 current. It reports no off-balance-sheet arrangements. The filing states cash was sufficient for operating activities, capital expenditures, and other obligations for one year from the financial-statement issuance date, while also warning that additional funding will be needed to support its plans.
Material changes versus the prior comparable period
- Operating cash use rose from $7.5 million to $11.5 million, reflecting higher operating activity and losses.
- R&D expense increased 19.5%. Contract research and clinical-trial expense was $5.9 million versus $6.4 million; the larger R&D increase came mainly from higher wages and salaries following team expansion.
- G&A expense increased 66.2%, primarily due to professional fees, directors’ and officers’ insurance, and salaries, including costs of operating as a public company.
- Cash increased by $24.7 million during 2022. Financing cash flow was $37.0 million, principally from the April 2022 IPO and partial over-allotment exercise. The company issued 6.0 million ADSs at $6.00 each and a further 772,091 ADSs; it reported approximately $38.0 million net IPO proceeds in its cash-flow presentation.
- All 7.8 million convertible preferred shares converted into ordinary shares upon the IPO. Ordinary shares outstanding were 24,898,908 at year-end 2022, versus 10,274,403 at year-end 2021.
Outlook, management commentary, risks and unusual items
- Development outlook: DRAGON, a Phase 3 tinlarebant trial in adolescent STGD1 patients, was underway; 42 participants had been enrolled by the filing’s March 29, 2023 latest practicable date. The company reported preliminary 12-month data from 13 Phase 2 participants and said it believed the data showed halted or slowed lesion growth. These small, open-label interim results are not conclusive evidence of efficacy.
- GA trial: PHOENIX, a Phase 3 study targeting approximately 430 GA patients, had been initiated by the latest practicable date; first-patient enrollment was expected around mid-2023. The trial’s primary endpoint is change in lesion growth over 24 months.
- Safety: Tinlarebant-related visual effects reported in STGD1 studies included delayed dark adaptation, transient xanthopsia or chromatopsia, and occasional night-vision impairment. Reported events were graded mild in the cited interim data; some remained ongoing at 12 months. Larger and controlled trials are needed to establish the benefit-risk profile.
- Funding: Management expects expenses and operating losses to increase as Phase 3 studies advance. It may need additional equity, debt, collaboration, or licensing funding; no committed external funding source is disclosed. Further equity issuance could dilute shareholders.
- Commitments: Remaining expected contractual costs for STGD1 clinical trials were approximately $19.1 million. The Columbia University license provides for up to $20 million in development and regulatory milestone payments and up to $25 million tied to a cumulative sales milestone, plus royalties and other specified payments. Timing and likelihood are contingent and not reasonably estimable in the filing.
- Banking event after year-end: A substantial majority of year-end cash had been held at Silicon Valley Bank. After SVB’s March 2023 closure, the company regained access to deposits and transferred substantially all of them to other banks; it reported no deposit losses and approximately $0.8 million still at SVB as of March 29, 2023.
- Going concern and controls: The prior-year auditor’s report included a going-concern explanatory paragraph citing recurring losses and financing needs. The 2022 auditor gave an unqualified financial-statement opinion, while management said year-end cash should fund operations for at least one year after issuance. A 2021 material weakness in risk assessment and internal-control policies was addressed through measures implemented in 2022; management said remediation would be complete once those measures were fully implemented. The 2022 filing does not include an auditor attestation on internal controls.
- Other principal risks: Clinical and regulatory failure or delay; dependence on tinlarebant; third-party CRO and manufacturing reliance; patent and Columbia license risks; competition; possible financing constraints; China-related regulatory, data, and geopolitical risks; and influence of controlling shareholder Lin Bioscience International Ltd., which beneficially owned approximately 65.94% of ordinary shares as of the latest practicable date.
Most important facts for investors to verify
- Review the audited statements and cash-flow assumptions, including whether the $42.1 million year-end cash balance and stated one-year funding horizon remain adequate as Phase 3 spending increases.
- Track DRAGON and PHOENIX enrollment, timelines, interim analyses, final endpoints, and complete safety data; distinguish controlled trial results from preliminary, small-cohort observations.
- Confirm the timing and potential cash impact of the $19.1 million STGD1 trial commitments and Columbia University milestone, royalty, and license obligations.
- Monitor financing needs, potential dilution, share-based compensation, and the effects of 3.6 million outstanding options reported at year-end.
- Check continued access to cash and deposit concentration after the SVB event, and assess the status of internal-control remediation and future auditor reporting.